Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1643-1650

  You, B ^a,b,c,d   Pollet Villard, M ^a,b,c,e   Fronton, L ^a,b   Labrousse, C ^a,b,c,e   Schott, A M ^a,b,f,g   Hajri, T ^a,b,c,e   Girard, P ^a,b   Freyer, G ^a,b,c   Tod, M ^a,b   Tranchand, B ^a,b,h   Colomban, O ^a,b   Ribba, B ^a,b,i   Raudrant, D ^a,b,c,e   Massardier, J ^a,b,c,e   Chabaud, S ^h   Golfier, F ^a,b,c,e  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e HÔTEL DIEU   (France)

^f UNIVERSITÉ DE LYON   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ INRIA RHÔNE ALPES   (France)

Author keywords

Biological serum tumor markers; Kinetics; Methotrexate; Predictive value of tests; Survival analysis; Trophoblastic neoplasms

Indexed keywords

CHORIONIC GONADOTROPIN; FOLINIC ACID; METHOTREXATE;

ADULT; ARTICLE; CHORIOCARCINOMA; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HIGH RISK PREGNANCY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL RATE; TROPHOBLASTIC TUMOR;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHORIONIC GONADOTROPIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; METHOTREXATE; PREGNANCY; RETROSPECTIVE STUDIES; RISK; ROC CURVE; SURVIVAL ANALYSIS;

EID: 77955232710     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq033     Document Type: Article

References (27)

1. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet 2002; 77: 285-287.
2. Golfier F, Raudrant D, Frappart L et al. First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol 2007; 196: 172-175.
3. Bagshawe KD, Dent J, Newlands ES et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989; 96: 795-802.
4. Chalouhi GE, Golfier F, Soignon P et al. Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol 2009; 200: 643-646.
5. Foulmann K, Guastalla JP, Caminet N et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 2006; 102: 103-110.
6. van Trommel NE, Massuger LF, Schijf CP et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24: 52-58.
7. Kerkmeijer LG, Thomas CM, Harvey R et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 2009; 100: 979-984.
8. Savage P, Seckl M, Short D. Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med 2008; 53: 774-780.
9. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984; 15: 153-171.
10. You B, Girard P, Paparel P et al. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate 2009; 69: 1325-1333.
11. You B, Perrin P, Freyer G et al. Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochemistry 2008; 41: 785-795.
12. hCG-AFP, a dynamic kinetic marker characterizing tumor marker decline of non seminomatous germ cell tumors (NSGCT) intermediate-poor risk patients according to the IGCCCG. Proc ASCO 2009. J Clin Oncol 2009; 27(Suppl): 5085.
13. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 2001; 11: 73-77.
14. Beal SL, Sheiner LB, Boeckmann A. NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions 2006.
15. Norman RJ, Buchholz MM, Somogyi AA et al. hCGbeta core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG. J Endocrinol 2000; 164: 299-305.
16. Brendel K, Dartois C, Comets E et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-234.
17. Dartois C, Brendel K, Comets E et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007; 64: 603-612.
18. Chan KK, Huang Y, Tam KF et al. Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2006; 195: 1282-1286.
19. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
20. Duval V, Karlsson MO. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res 2002; 19: 1835-1840.
21. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
22. Tham KF, Ratnam SS. The classification of gestational trophoblastic disease: a critical review. Int J Gynaecol Obstet 1998; 60 (Suppl 1): S39-S49.
23. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112: 654-662.
24. Growdon WB, Wolfberg AJ, Goldstein DP et al. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2009; 112: 353-357.
25. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112: 654-662.
26. Garrett AP, Garner EO, Goldstein DP et al. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 2002; 47: 355-362.
27. Matsui H, Suzuka K, Yamazawa K et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol 2005; 96: 616-620.